SCHEMBL2641099

SCHEMBL2641099

N#Cc1cccc(OCCn2ccnc(N3CCNCC3)c2=O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.54
TBXAS1 P24557 1/20 0.49
CYP1A2 P05177 5/20 0.43
CYP3A4 P08684 4/20 0.43
CASP1 P29466 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HIF1A Q16665 2/20 0.43
CYP2C9 P11712 2/20 0.43
HPGD P15428 2/20 0.43
CASP7 P55210 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ALOX15 P16050 1/20 0.43
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
CLK4 Q9HAZ1 1/20 0.41
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2641342 0.89 HRH3 (0.48) HTR2CTBXAS1
SCHEMBL2641132 0.87 HTR2C (0.47) HTR2CTBXAS1ALDH1A1KDM4EHTR6
SCHEMBL2641416 0.86 HTR6 (0.46) HTR2CCYP1A2CYP3A4CASP1ALDH1A1
SCHEMBL2641183 0.86 KDM4E (0.42) HTR2CALDH1A1KDM4EHTR6
SCHEMBL2640922 0.86 HTR1A (0.47) HTR2CALDH1A1DRD2KDM4EHTR6
SCHEMBL2641753 0.85 LTA4H (0.47) HTR2CCYP1A2CYP3A4CASP1ALDH1A1
SCHEMBL2640994 0.85 HTR2C (0.43) HTR2CALDH1A1LMNAKDM4EHTR6
SCHEMBL2641217 0.83 HRH3 (0.47) HTR2CTBXAS1ALDH1A1CYP2C9HPGD
SCHEMBL2640904 0.83 LTA4H (0.46) HTR2CHTR6
SCHEMBL2641295 0.83 HTR2C (0.40) HTR2CCYP1A2CYP3A4ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4831966-B2 2011-12-07 JP claimed
US-7244722-B2 Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones BIOVITRUM AB (SE) 2007-07-17 US claimed
EP-1534391-B1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS BIOVITRUM AB (SE) 2007-02-14 EP claimed
EP-1534391-A1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS Biovitrum AB (SE) 2005-06-01 EP claimed
US-20040063693-A1 Compounds BIOVITRUM AB (SE) 2004-04-01 US claimed
WO-2004009586-A1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS BIOVITRUM AB (SE) 2004-01-29 WO claimed
US-7244722-B2 Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones BIOVITRUM AB (SE) 2007-07-17 US disclosed
EP-1534391-B1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS BIOVITRUM AB (SE) 2007-02-14 EP disclosed
EP-1534391-A1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS Biovitrum AB (SE) 2005-06-01 EP disclosed
US-20040063693-A1 Compounds BIOVITRUM AB (SE) 2004-04-01 US disclosed
WO-2004009586-A1 NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS BIOVITRUM AB (SE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063693-A1 Compounds HTR1A, HTR1B, HTR2C HTR2C 3/4885TBXAS1 640/4885CYP1A2 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.